Global Chinese Hamster Ovary (CHO) Cells Market, By Type (Services and Product), System (Metabolic Selection System, Antibiotic Selection System and Others), Application (Biologics and Medical Research), End User (Biopharmaceutical Companies, Biotechnology Companies, Clinical Development and Manufacturing Organizations, Clinical Research Organizations, Academic Institutes and Research Organizations, Others), Distribution Channel (Direct Tenders, Retail Sales and Others) – Industry Trends and Forecast to 2031.
Chinese Hamster Ovary (CHO) Cells Market Analysis and Size
In the Chinese hamster ovary (CHO) cells market, advancements have revolutionized biopharmaceutical production. With their versatility, CHO cells offer benefits such as increased yield and improved protein quality, driving their widespread adoption in biotech research and drug development. This market witnesses continuous innovation, propelling the biopharmaceutical industry forward. As demand for biologics surges, CHO cells remain pivotal, ensuring efficient production and meeting the needs of the expanding pharmaceutical market.
Global Chinese hamster ovary (CHO) cells market size was valued at USD 384,141.81 thousand in 2023, is projected to reach USD 737,784.42 thousand by 2031, with a CAGR of 8.5% during the forecast period 2024 to 2031. This indicates that the market value. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Thousand, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Services and Product), System (Metabolic Selection System, Antibiotic Selection System and Others), Application (Biologics and Medical Research), End User (Biopharmaceutical Companies, Biotechnology Companies, Clinical Development and Manufacturing Organizations, Clinical Research Organizations, Academic Institutes and Research Organizations, Others), Distribution Channel (Direct Tenders, Retail Sales and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Thermo Fisher Scientific Inc. (U.S.), AcceGen (U.S.), RayBiotech Life, Inc. (U.S.), CLS Cell Lines Service GmbH (Germany), BPS Bioscience, Inc. (U.S.), GenTarget Inc. (U.S.), Merck KGaA (Germany), Promega Corporation (U.S.), Abeomics (U.S.), Applied Biological Materials Inc. (abm) (Canada), ATCC (U.S.), Sartorius AG (Germany), Lonza (Switzerland), Horizon Discovery Ltd. (U.K.), Cytiva (U.S.), GTP Bioways (U.S.), Curia Global, Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Chinese hamster ovary (CHO) cells are a commonly used cell line in biotechnology and pharmaceutical research. These cells, derived from the ovaries of the Chinese hamster, offer advantages such as rapid growth, easy cultivation, and the ability to produce complex proteins. CHO cells are extensively utilized in the production of therapeutic proteins, vaccines, and monoclonal antibodies due to their capability for high-yield protein expression and post-translational modifications.
Chinese Hamster Ovary (CHO) Cells Market Dynamics
Drivers
- Increasing Prevalence of Chronic Diseases
The global rise in chronic diseases such as cancer, autoimmune disorders, and infectious diseases is fueling demand for biopharmaceuticals. As these conditions become more prevalent, there is a growing need for effective treatments, leading to increased production of biologics. CHO cells play a crucial role in this process, being widely used for biopharmaceutical manufacturing due to their ability to produce complex proteins. This trend propels the growth of the CHO cell market worldwide.
- Growing Biopharmaceutical Industry
The surging demand for biopharmaceuticals, including monoclonal antibodies, vaccines, and recombinant proteins, is fueling the expansion of the CHO cell market. CHO cells excel in producing these biologics due to their capacity for post-translational modifications and high protein expression levels. For instance, the production of monoclonal antibodies such as rituximab and trastuzumab heavily relies on CHO cells, highlighting their pivotal role in meeting the escalating demand for biopharmaceuticals.
Opportunities
- Advancements in Cell Line Engineering Technologies
Advancements in cell line engineering, such as CRISPR/Cas9, are revolutionizing CHO cell development. Through precisely editing the genome, researchers can enhance productivity and stability, key factors in biopharmaceutical production. For instance, targeted modifications can optimize protein expression or streamline metabolic pathways, resulting in higher yields and better product quality. These innovations are driving the expansion of the Chinese hamster ovary cells market by offering more efficient and reliable production platforms.
- Expansion of Contract Development and Manufacturing Organizations (CDMOs)
The outsourcing trend in biopharmaceutical manufacturing to contract development and manufacturing organizations (CDMOs) is escalating, fueled by the imperative for adaptable production capabilities and specialized expertise. Numerous CDMOs rely on CHO cell-based systems for bioproduction, heightening the demand for CHO cell culture products and services. This surge underscores the pivotal role of CDMOs in meeting the burgeoning demands of the biopharmaceutical industry while leveraging CHO cell technology for efficient production.
Restraints/Challenges
- Supply Chain Vulnerabilities
The CHO cell market grapples with susceptibility to supply chain disruptions due to its dependence on a limited number of suppliers for cell lines and culture media. Such vulnerabilities pose significant risks to production schedules and product availability, potentially leading to delays and shortages in the market.
- High Cost of Production
The high costs of producing, maintaining, and scaling up CHO cell cultures pose significant barriers to adoption, particularly for smaller biotech firms and academic institutions with constrained budgets. These expenses encompass the procurement of Chinese hamster ovary cell line, culture media, specialized equipment, and skilled personnel, making it challenging for organizations with limited resources to engage in biopharmaceutical research and production using CHO cells.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In July 2023, Merck KGaA unveiled plans for expanding its Lenexa, Kansas facility, adding 9,100 square meters of laboratory space and enhancing production capacity for cell culture media. This strategic move aligns with the company's goal to bolster its supply chain, catering to the escalating demand for Chinese hamster ovary cell culture platforms
- In February 2023, the European Investment Bank (EIB) finalized an €18 million deal with Estonia-based biotech firm, Icosagen AS. The funding will bolster Icosagen's production facility and advance its research & development technology platforms, reinforcing its position as a frontrunner in biotechnology innovation
- In February 2022, Sartorius AG completed the acquisition of Novasep's business, augmenting its chromatography portfolio. This addition includes systems tailored for small biomolecules such as oligonucleotides, peptides, and insulin, as well as innovative platforms for continuous biopharmaceutical production, bolstering Sartorius' offerings in the biopharma sector
- In January 2021, Pfizer announced a USD 120 million investment in biotechnology innovation through the Pfizer Breakthrough Growth Initiative (PBGI). This initiative, part of a larger commitment of up to USD 500 million, aims to support biotech startups with funding and access to Pfizer's scientific expertise, fostering breakthroughs in the field
Chinese Hamster Ovary (CHO) Cells Market Scope
The market is segmented on the basis of type, system, application, end user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Services
- Product
System
- Metabolic Selection System
- Antibiotic Selection System
- Others
Application
- Biologics
- Medical Research
End User
- Biopharmaceutical Companies
- Biotechnology Companies
- Clinical Development and Manufacturing Organizations
- Clinical Research Organizations
- Academic Institutes and Research Organizations
- Others
Distribution Channel
- Direct Tenders
- Retail Sales
- Others
Chinese Hamster Ovary (CHO) Cells Market Regional Analysis/Insights
The market is analysed and market size insights and trends are provided by country, type, system, application, end user, and distribution channel as referenced above.
The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to dominate the Chinese hamster ovary (CHO) cells market, sustained by key market players and the region's status as the largest consumer market with a high GDP. The concentration of industry leaders further solidifies its position as a frontrunner in CHO cell technologies.
Asia-Pacific is expected to show significant growth in the Chinese hamster ovary (CHO) cells market, driven by China's dominance in the region. Mass production of CHO cells-based products, coupled with rising demand from emerging markets and expansion initiatives, underpins this growth trajectory.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.
Competitive Landscape and Chinese Hamster Ovary (CHO) Cells Market Share Analysis
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
Some of the major players operating in the market are:
- Thermo Fisher Scientific Inc. (U.S.)
- AcceGen (U.S.)
- RayBiotech Life, Inc. (U.S.)
- CLS Cell Lines Service GmbH (Germany)
- BPS Bioscience, Inc. (U.S.)
- GenTarget Inc. (U.S.)
- Merck KGaA (Germany)
- Promega Corporation (U.S.)
- Abeomics (U.S.)
- Applied Biological Materials Inc. (abm) (Canada)
- ATCC (U.S.)
- Sartorius AG (Germany)
- Lonza (Switzerland)
- Horizon Discovery Ltd. (U.K.)
- Cytiva (U.S.)
- GTP Bioways (U.S.)
- Curia Global, Inc. (U.S.)
SKU-